Search research articles
Contact Us
Filters
Showing results (71-80 of 139) with videos related to
Page
of 14
Sort By:
Anticancer Research
|
March 2, 2018
<i>COX2/PTGS2</i> Expression Is Predictive of Response to Neoadjuvant Celecoxib in <i>HER2</i>-negative Breast Cancer Patients
Patricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, et al.
Age and Ageing
|
February 12, 2024
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach
Meoïn Hagège, Michaël Bringuier, Claudia Martinez-Tapia, et al.
The Lancet. Oncology
|
January 2, 2021
Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative
Martine Extermann, Etienne Brain, Beverly Canin, et al.
Breast (Edinburgh, Scotland)
|
February 19, 2026
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer
Timothé Guinel, Amélie Lusque, Audrey Mailliez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Anne-Sophie Hamy, Hélène Bonsang-Kitzis, Diane De Croze, et al.
Cancers
|
December 1, 2020
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy
Romuald Le Scodan, Denise Stevens, Etienne Brain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
Sylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
Breast Cancer Research and Treatment
|
December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Hope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 139) with videos related to
Sort By:
Page
of 14
Anticancer Research
|
March 2, 2018
<i>COX2/PTGS2</i> Expression Is Predictive of Response to Neoadjuvant Celecoxib in <i>HER2</i>-negative Breast Cancer Patients
Patricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, et al.
Age and Ageing
|
February 12, 2024
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach
Meoïn Hagège, Michaël Bringuier, Claudia Martinez-Tapia, et al.
The Lancet. Oncology
|
January 2, 2021
Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative
Martine Extermann, Etienne Brain, Beverly Canin, et al.
Breast (Edinburgh, Scotland)
|
February 19, 2026
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer
Timothé Guinel, Amélie Lusque, Audrey Mailliez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Anne-Sophie Hamy, Hélène Bonsang-Kitzis, Diane De Croze, et al.
Cancers
|
December 1, 2020
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy
Romuald Le Scodan, Denise Stevens, Etienne Brain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
Sylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
Breast Cancer Research and Treatment
|
December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Hope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Page
of 14